The pleiotropic effects of mTOR inhibitors

Journal of Nephrology

Volumn 17, Issue 6, 2004, Pages 762-768

  Ponticelli, Claudio ^a,b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b NONE   (Italy)

Author keywords

Everolimus; Immunosuppression; mTOR inhibitors; Renal transplantation; Sirolimus

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; CYTOPLASMIC RECEPTOR; EVEROLIMUS; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN KINASE; RAPAMYCIN; RITUXIMAB; VASCULOTROPIN; ANTIVIRUS AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTERY INTIMA; CELL CYCLE G1 PHASE; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOWNSTREAM PROCESSING; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; EXPERIMENTAL DESIGN; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PLEIOTROPY; PROTEIN DEPLETION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REGULATORY MECHANISM; RETROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; THROMBOCYTOPENIA; TRANSLATION REGULATION; VASCULAR DISEASE; VIRUS REPLICATION; ANIMAL; DRUG EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PROTEIN KINASES; SIROLIMUS; VASCULAR DISEASES;

EID: 16644385561     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Schmelzle T, Hall MN. mTOR a central controller of cell growth. Cell 2000; 103: 253-62.
2. Sehgal SN. Rapamune (sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monitor 1995; 17: 660-5.
3. Kovarik JM. Everolimus. A proliferation signal in hibitor targeting primary causes of allograft dysfunction. Drugs Today 2004; 40: 101-9.
4. Murase N, Starzl TE, Ye Q, Tsamandas A, Thomson AW, Rao AS, Demetris AJ. Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation with particular reference to the liver. Transplantation 1996; 61: 1-4.
5. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994; 76: 263-74.
6. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA, Gray GS, Nadler LM. Cloning of B7-2: A CTLA-4-counter-receptor that costimulates human T cell proliferation. Science 1993; 262: 909-11.
7. Li XC, Roy-Chaudhury P, Hancock WW, Manfro R, And MS, Li Y, Zheng XX, Nickerson PW, Steiger J, Malek TR, Strom TB. IL-2 and IL-4 double knockout mice reject islet allografts: A role for novel T cell growth factors in allograft rejection. J Immunol 1998; 161: 890-6.
8. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-45.
9. Abraham RT. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998; 10: 330-6.
10. Kahan BD for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute allograft rejection: A randomised multicentre study. Lancet 2000; 356: 194-202.
11. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurti V, Mastroianni B, Savas K, Cook DJ, Novick AL. Kidney transplantation without calcineurin inhbitor drugs: A prospective randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-6.
12. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol J, Durand D, Wrammer L, Battstram C, Charpentier B. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036-42.
13. Vitko S, Tedesco H, Eris J, Pascual J, Whelchel J, Magee J, Campbell S, Civati G, Bourbigot B, Alves-Filho G, Leone J, Garcia VD, Rigotti P, Esmeraldo R, Cambi V, Haas T, Jappe A, Bernhardt P, Geissler J, Cretin N. Everolimus with optimal cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized trials. Am J Transplant 2004; 4: 626-35.
14. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-Von Kaeppler H, Starling RC, Sorensen K, Kummel M, Lind JM, Abeywickrama KH, Bernhardt P. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003; 349: 847-58.
15. Sheil AG. Organ transplantation and malignancy: inevitable linkage. Transplant Proc 2002; 34: 2436-7.
16. Penn I. De novo cancers in organ allograft recipients. Curr Opin Organ Transplant 1998; 3: 188-96.
17. Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev 1981; 8: 63-7.
18. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY 22,989) against transplanted tumors. J Antibiot 1984; 37: 1231-7.
19. Sawyers CL. Will mTOR inhibitor make it as cancer drug? Cancer Cell 2003; 4: 343-8.
20. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphate functions as a negative regulator of the phosphoinositide-3-kinase/Akt pathway. Proc Natl Acad Sci USA 1998; 95: 15587-91.
21. Brennan P, Mehl AM, Jones M, Rowe M. Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene 2002; 21: 1263-71.
22. Mirza AM, Kohn AD, Roth RA, McMahon M. Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. Cell Growth Diff 2000; 11: 279-82.
23. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL. Enhanced sensitivity of PTEN deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-9.
24. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004; 100: 657-66.
25. Shi Y, Gera J, Hu L, Hsu JH, Bookstein Li W, Lichtenstein A. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002; 62: 5027-34.
26. Majewski M, Korecka M, Joergensen J, Fields L, Kossev V, Schuler W, Shaw L, Wasik MA. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710-7.
27. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63: 4472-80.
28. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agent used in organ transplantation. Transplantation 2004; 77: 1777-82.
29. Guba V, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35.
30. Luan FL, Ding R, Sharma VK, Con WJ, Lagman M, Suthantiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917-26.
31. Abraham RT. mTOR a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol 2004; 279: 299-319.
32. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG jr. TSC2 regulates VEGF through mTOR-dependent and independent pathways. Cancer Cell 2003; 4: 147-58.
33. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor/phosphatidylinositol 3 kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-6.
34. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002; 62: 5645-50.
35. Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: 1319-26.
36. Garcia UD, Bonamigo Filho JL, Neumann J, Foglietto L, Geiger AM, Garcia CD, Barros V, Keitel E, Birtar AE, Ferrera des Santos A, Roithman S. Rituximab in association with rapamycin for posttransplant lymphoproliferative disease. Transpl Int 2003; 16: 202-6.
37. Kahan BD, Knight R, Schoenberg L, Pobielski J, Kerman RH, Mahalati K, Yagupoklu Y, Aki ET, Van Buren CT. Ten years of sirolimus therapy for human renal transplantation. The University of Texas at Houston experience. Transplant Proc 2003; 35: S25-34.
38. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004; 18: 446-9.
39. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW, Kasiske BL, Kahan BD. mTOR inhibitor maintenance immunosuppression is associated with a reduced incidence of posttransplant malignancies. Internat Congress of the Transplantation Society, Vienna, 2004; abstr 79.
40. Yarosh DB, Cruz PD, Dougherty I, Bizios N, Kibitel J, Goodtzova K, Goldfarb S, Green B, Brown D. FRAP DNA-dependent protein kinase mediates a late signal transduced from ultraviolet-induced DNA damage. J Invest Dermatol 2000; 114: 1005-10.
41. Euvrard S, Ulrich C, Lefrancois N. Immunosuppressant and skin cancer in transplant patients: Focus on rapamycin. Dermatol Sug 2004; 30: 628-33.
42. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462-70.
43. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001; 12: 848-55.
44. Fishman J, Rubin H. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-51.
45. Sagedal S, Nordal KP, Hartmann A, Sund S, Scott H, Degre M, Foss A, Leivestad T, Osnes K, Fauchald P, Rollag H. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850-6.
46. Geddes CC, Church CC, Collidge T, McCruden EA, Gillespie G, Matthews E, Hainmueller A, Briggs JD. Management of cytomegalovirus infection by weekly surveillance after renal transplant: Analysis of cost, rejection, and renal function. Nephrol Dial Transplant 2003; 18: 1891-8.
47. Tong CY, Bakran A, Peiris JS, Muir P, Herrington CS. The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation. Transplantation 2002; 27: 576-8.
48. Humar A, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, Matas AJ. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999; 68: 1879-83.
49. Avery RK. Viral triggers of cardiac-allograft dysfunction. N Engl J Med 2001; 344: 1545-7.
50. Wang X, Huong SM, Chiu ML, Raab-Traub N, Huang ES. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 2003; 424: 456-61.
51. Johnson RA, Wang X, Ma XL, Huong SM, Huang ES. Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: Inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol 2001; 75: 6022-32.
52. Sanchez V, McElroy AK, Spector DH. Mechanisms governing maintenance of cdk1/cyclin B1 kinase activity in cells infected with human cytomegalovirus. J Virol 2003; 77: 13214-24.
53. Smith MS, Bentz GL, Smith PM, Bivins ER, Yurochko AD. HCMV activates PI3K in monocytes and promotes monocyte motility and transendothelial migration in a PI3K-dependent manner. J Leukoc Biol 2004; 76: 65-76.
54. Evers DL, Wang X, Huong SM, Huang DY, Huang ES. 3,4′,5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling. Antiviral Res 2004; 63: 85-95.
55. Trotter J, Wallack A, Steinberg T. Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid therapy. Transpl Infect Dis 2003; 5: 174-80.
56. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T, on behalf of 156 Study Group. Everolimus in combination with reduced-exposure cyclosporine in de novo renal transplant recipients: Results of a 3-year phase II, randomized, multicenter, open-label study. Transplantation (in press).
57. Ponticelli C, Sandrini S, Casciani C, Schena P. A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine. XX Internat Congress of the Transplantation Society, Vienna 2004; abstr 432.
58. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-2.
59. Hall AV, Jevnikar AM. Significance of endothelial cell survival programs for renal transplantation. Am J Kidney Dis 2003; 41: 1140-54.
60. Avery RK. Cardiac-allograft vasculopathy. N Engl J Med 2003; 349: 845-6.
61. Keck BM, Bennett LE, Rosendale J, Daily OP, Novick RJ, Hosenpud JD. Worldwide thoracic organ transplantation: A report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. Clin Transplant 1999; 13: 35-49.
62. Hancock WH, Whitley WD, Tullis SG, Heemann UW, Wasowska B, Baldwin WM 3rd, Tilney NL. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993; 56: 643-50.
63. Riesterer O, Zinng D, Hummerjohann J, Bodis S, Pruschy M. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene 2004; 23: 4624-35.
64. Martin KA, Rzuicidlo EM, Merenick BL, Fingar DC, Brown DJ, Wagner RJ, Powell RJ. The mTOR/ p70S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Cell Physiol 2004; 286: C507-17.
65. Gregory CR, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor,and cytokine response in injured vessels. Transplantation 1993; 55: 1409-18.
66. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse R, Billingham ME, Morris RE. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59: 655-61.
67. Schmid C, Heemann U, Azuma H, Tilney NL. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts. Transplantation 1995; 60: 729-33.
68. Ikonen TS, Gummert JF, Serkova N, Hayase M, Honda Y, Kobayase Y, Hausen B, Yock PG, Christians U, Morris RE. Efficacies of sirolimus (rapamycine) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening. Transpl Int 2000; 13 (suppl 1): S314-20.
69. Schachner T, Zou Y, Oberhuber A, Tzankof A, Mairinger T, Laufer G, Bonatti JO. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg 2004; 77: 1580-5.
70. Sousa JE, Costa MA, Abizaid AC, Rensig BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Sustained suppression of neointimal poliferation by sirolimus-eluting stents: One year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104: 2007-11.
71. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R, RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2000; 346: 1773-80.
72. Mancini D, Pinney S, Burkhoff D, La Manca J, Itescu S, Burke E, Edwards N, Oz M, Marks AR. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.
73. Shihab FS, Bennett WM, Yi H, Choi S-O, Andoh TF. Sirolimus increases transforming growth factor-βI expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65: 1262-71.